Studying relmacabtagene autoleucel cell therapy in adults with B-cell lymphoma
Observes relmacabtagene autoleucel, a cell therapy, in adults with B-cell lymphoma.
Key facts
- Who runs it
- Shanghai Ming Ju Biotechnology Co., Ltd.
- Where
- Beijing, ChinaSee the 2 sites
- Trial code
- Registry title
- Relmacabtagene Autoleucel in Hematologic Malignancies
- Status
- Not yet recruiting
- People taking part
- 150 people, planned
- Started
- 28 Dec 2023
- Expected to end
- 31 Dec 2038
- Type of study
- Observational
- Treatments tested
- Relmacabtagene Autoleucel
- Record updated
- 21 November 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with blood cancers who have been treated with Relma-cel, including off-label use, to see how well and how safely it works in real life.
- Age
- 18 years and older
- Sex
- All sexes can join
- Earlier treatment
- Must have been treated with Relma-cel, including off-label products. Anyone in an earlier study must have finished, left or been lost to follow-up there.
Main reasons for not taking part
- Treated with Relma-cel and then with other CAR-T products
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Signed informed consent
- Patients who have been treated with Relma-cel, including those who have received off-label products
- If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study
Who cannot take part
- 1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products
Where in China
- Beijing Cancer HospitalBeijing, ChinaContact: Yuqing Song, PhDNo longer taking part
- Peking University International HospitalBeijing, ChinaContact: Xinjian LiuNo longer taking part
About the trial
What the trial wants to find out
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
The group in the trial
- Relmacabtagene Autoleucel
Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
- Plain-language title
- Studying relmacabtagene autoleucel cell therapy in adults with B-cell lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 November 2023